A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: A European perspective
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Previous comparative reviews of add-on therapies for patients with major depressive disorder (MDD) with an inadequate response to antidepressants have not used meta-analytic techniques to compare different drug classes and have included non-licensed therapies. This meta-analysis reviewed all published peer-reviewed evidence for the efficacy of EU-licensed therapies in patients with MDD and an inadequate response to antidepressant monotherapy. Papers concerning randomized clinical trials (RCTs) were identified using criteria from the Cochrane Handbook for Systematic Reviews of Interventions. Add-on therapies reviewed were antidepressants, quetiapine XR, lithium, and S -adenosyl- l -methionine (SAMe). Seven RCTs that reported response and remission in a way that allowed quantitative analysis were included in this meta-analysis. Comparison of the different drug classes indicated that most interventions had similar efficacy. The likelihood of response was significantly greater with SAMe versus placebo and lithium and with quetiapine XR versus placebo. Most add-on interventions demonstrated comparable efficacy in patients with MDD and an inadequate response to initial antidepressants. However, there is currently a paucity of high-quality data regarding the use of add-on treatments in patients with MDD who are inadequate responders to antidepressants, with quetiapine XR presenting the most comprehensive evidence base to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Affective disorders and suicide risk: a reexamination
Bostwick, J. M., & Pankratz, V. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1925 · Cited by 878 · cited 1×
“5%, respectively) (Bostwick and Pankratz, 2000).”
Judd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1501 · Cited by 458
Birnbaum, H. G., Kessler, R. C., Kelley, D., Ben-Hamadi, R., Joish, V. N., & Greenberg, P. E. (2010) · Depression and Anxiety · doi:10.1002/da.20580 · Cited by 380 · cited 1×
“, 2003), with almost one-third of patients with severe MDD reporting unemployment or work disability (Birnbaum et al., 2010).”
BackgroundMasand, P., & Gupta, S. (2002) · Annals of Clinical Psychiatry · doi:10.3109/10401230209147454 · Cited by 311 · cited 1×
“Given that relatively few patients respond to their first-line antidepressant therapy (Rush, 2007) and that patients being treated with mirtazapine (and indeed any other agent) may experience unwanted side effects (Masand and Gupta, 2002), options from other drug classes are especially welcome.”
BackgroundPapakostas, G. I., Mischoulon, D., Shyu, I., Alpert, J. E., & Fava, M. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09081198 · Cited by 297
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01262-8 · Cited by 244
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
A Systematic Review of Augmentation Strategies for Patients with Major Depressive Disorder
Fleurence, R., Williamson, R., Jing, Y., Kim, E., Tran, Q.-V., Pikalov, A., & Thase, M. E. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4089 · Cited by 65
Cited by
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citationReinforcement learning in depression: a review of computational research
Chen, C., Takahashi, T., Nakagawa, S., Inoue, T., & Kusumi, I. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.005 · Cited by 233
Noninvasive brain stimulation treatments for addiction and major depression
Dunlop, K., Hanlon, C. A., & Downar, J. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12985 · Cited by 171
Woo, Y., Seo, H.-J., McIntyre, R., & Bahk, W.-M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010080 · Cited by 79
“Despite the introduction of a number of antidepressant drugs and their prolonged clinical use, many patients with depression show an inadequate response to standard antidepressant therapy [1–4].”
BackgroundPharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
“, 2013a), a randomized open comparison with lamotrigine in which lithium was nonsignificantly better (Schindler and Anghelescu, 2007a), and a meta-analysis of EU-licensed augmenters with similar response rates for lithium, quetiapine XR, and S-adenosyl-L-methionine, though S-adenosyl-L-methionine was significantly bet…”
ResultSelf-citation
Metadata
- Authors
- Turner, P., Kantaria, R., & Young, A. H.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-10-09
- Volume
- 28
- Issue
- 2
- Pages
- 85-98
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2128433422
- Cited by
- 28
- References
- 9
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: A European perspective. https://app.cochat.ai/papers/10.1177/0269881113507640
- The paper
- Turner, P., Kantaria, R., & Young, A. H. (2014). A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: A European perspective. Journal of Psychopharmacology. https://doi.org/10.1177/0269881113507640
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.